Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines

Vaccine

Volumn 17, Issue 9-10, 1999, Pages 1251-1263

  Costantino, Paolo ^a   Norelli, Francesco ^a   Giannozzi, Aldo ^a   D'Ascenzi, Sandro ^a   Bartoloni, Antonella ^a   Kaur, Surinder ^b   Tang, Dazhi ^b   Seid, Robert ^b   Viti, Stefano ^a   Paffetti, Roberto ^a   Bigio, Massimo ^a   Pennatini, Carlo ^a   Averani, Giovanni ^a   Guarnieri, Valentina ^a   Gallo, Eugenia ^a   Ravenscroft, Neil ^a   Lazzeroni, Carla ^a   Rappuoli, Rino ^a   Ceccarini, Costante ^a  

^a CHIRON VACCINES   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Capsular polysaccharide; Conjugate vaccines; Hydrolysis; Intermediate chain length oligomers; Oligosaccharide; Size fractionation

Indexed keywords

BACTERIAL POLYSACCHARIDE; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE;

ARTICLE; BACTERIAL MEMBRANE; CHROMATOGRAPHY; DRUG MANUFACTURE; FRACTIONATION; HAEMOPHILUS INFLUENZAE TYPE B; HYDROLYSIS; MASS SPECTROMETRY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL;

ANTIGENS, BACTERIAL; BACTERIAL CAPSULES; CHROMATOGRAPHY, ION EXCHANGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS VACCINES; HYDROLYSIS; MASS SPECTROMETRY; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; ULTRAFILTRATION; VACCINES, CONJUGATE;

EID: 0033525926     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00348-X     Document Type: Article

References (38)

1. Wright P.F. Approaches to prevent acute bacterial meningitis in developing countries. Bull WHO. 67(5):1989;479-486.
2. Costantino P., Viti S., Podda A., Velmonte M.A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 10:1992;691-697.
3. Daum RS, Granoff DM. Lessons from the evaluation of immunogenicity. In: Ellis RW, Granoff DM, editors. Development and clinical uses of Haemophilus b conjugate vaccines. New York: Marcel Dekker, 1994. p. 291-312.
4. Decker M.D., Edwards K.M., Bradley R., Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr. 120:1992;184-189.
5. Szu S.C., Li X., Schneerson R., Vickers J.H., Bryla D., Robbins J.B. Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect Immun. 57:1989;3823-3827.
6. Dintzis R.Z., Okajima M., Middleton M.H., Greene G., Dintzis H.M. The immunogenicity of soluble haptenated polymers is determined by molecular mass and hapten valence. J Immunol. 143:1989;1239-1244.
7. Wessels M.R., Paoletti L.C., Guttormsen H., Michon F., D'Ambra A.J., Kasper D.L. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy. Infect Immun. 66:1998;2186-2192.
8. Paoletti L.C., Kasper D.L., Michon F., Di Fabio J., Jennings H.J., Tosteson T.D., Wessels M.R. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates. J Clin Invest. 89:1992;203-209.
9. Anderson P.W., Pichichero M.E., Insel R.A., Betts R., Eby R., Smit D.H. Vaccines consisting of periodate-cleaved oligosaccharides from the capsule of Haemophilus influenzae type b coupled to a protein carrier: structural and temporal requirements for priming in the human infants. J Immunol. 137:1986;1181-1186.
10. Kabat EA. In: Structural concepts in immunology and immunochemistry. New York: Holt, Rinehart and Wiston, 1968. p. 82-111.
11. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Mokatrin A., Raff H.P., Costantino P., Ceccarini C., Granoff D.M. Biocine meningococcal C (Men C) conjugate vaccine elicits high titers of serum bactericidal activity in toddlers (SPR Abstract 1053). Pediatric Res. 39:1996;178A.
12. Shackley FM, Heath PT, Flamank C, MacLennan JM, Herbert M, Granoff DM, Forrest BD, Moxon ER. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine in British children (Abstract). Annual Meeting of The Infectious Disease Society of America, New Orleans, LA, September 18-20, 1996.
13. Joint Commission on Biological Nomenclature Abbreviated terminology of oligosaccharide chains. Recommendations 1980. Eur J Biochem. 126:1982;433-437.
14. Colorimetric analysis of sugar. Methods Enzymol 3:73-105.
15. Chen P.S., Toribara T.Y., Warner H. Microdetermination of phosphorus. Anal Chem. 28:1956;1756-1758.
16. Anderson P., Pichichero M.E., Insel R.A. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM 197. J Clin Invest. 76:1985;52-59.
17. Kabat EA, Mayer MM. Experimental immunochemistry. 2nd ed. Springfield, IL: C.C. Thomas, 1961.
18. Svennerholm L. Quantitative estimation of sialic acids II. A colorimetric resorcinol hydrochloric method. Biochem Biophys Acta. 24:1957;604-611.
19. Hestrin S. The reaction of acetyl choline and other carboxylic acid derivatives with hydroxylamine and its analytic application. J Biol Chem. 180:1949;249-261.
20. Nash T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. J Biochem. 55:1953;416-421.
21. Lifely M.R., Nowicka U.T., Moreno C. Analysis of the chain length of oligomers and polymers of sialic acid isolated from Neisseria meningitidis group B and C and Escherichia coli k1 and k92. Carbohydrate Res. 156:1986;123-135.
22. D'Ambra A.J., Baugher J.E., Concannon P.E., Pon R.A., Michon F. Direct and indirect methods for molar-mass analysis of fragments of the capsular polysaccharide of Haemophilus Influenzae type b. Anal Biochem. 250:1997;228-236.
23. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., Achtman M., Densen P., Frash C.E., Kayhty H., Mays J.P., Nencioni L., Peeters C., Phipps D.C., Poolman J.T., Rosenqvist E., Siber G.R., Thiesen B., Tai J., Thompson C.M., Vella P.P., Wenger J.D. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microb. 32:1994;1475-1482.
24. Crisel R.M., Backer R.S., Dorman D.E. Capsular polymer of Haemophilus influenzae type b. I. Structural characterization of capsular polymer of strain Eagan. J Biol Chem. 250:1975;4926-4930.
25. Fenn J.B., Mann M., Meng C.K., Wong S.F., Whithouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science. 246:1989;64-71.
26. Jennings H.J., Bhattacharjee A.K., Bundle D.R., Kenny C.P., Martin A., Smith I.C.P. Structure of the capsular polysaccharides of N. meningitidis as determined by 13C NMR spectroscopy. J Infect Dis. 136:1977;S78-S83.
27. Bundle D.R., Smith I.C.P., Jennings H.J. Determination of the structure and conformation of bacterial polysaccharide by carbon 13 nuclear magnetic resonance. Studies on the group specific antigens of Neisseria meningitidis serogroups A and X. J Biol Chem. 249:1974;2275-2281.
28. Adams W.G., Deaver K.A., Cochi S.L., Plikatis B.D., Zell E.R., Broome C.V., Wenger J.D. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 269:1993;221-226.
29. Eskola J., Takala A.K., Kaythy H., Peltola H., Makela P.H. Experience in Finland with Haemophilus influenzae type b vaccines. Vaccine. 9 (Suppl.):1993;514-516.
30. Schneerson R., Robbins J.B., Parke J.C. Jr., Bell C., Schlesselman J.J., Sutton A., Wong Z., Schiffman G., Karpas A., Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus Influenzae type b and pneumococcal type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 52:1986;519-528.
31. Eskola J., Kayhty H., Peltola H., Kkaranko V., Makela P.H., Samuelson J., Gordon L.K. Antibody levels achieved in infants by a course of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine. Lancet. 1:1985;1184-1186.
32. Einhorn M.S., Weinberg G.A., Anderson E.L., Granofff P.D., Granoff D.M. Immunogenicity in infants of Haemophilus influenzae type b polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet. 2:1986;299.
33. Granoff D.M., Anderson E.L., Osterholm M.T., Holmes S.J., McHugh J.E., Belshe R.B., Medley F., Murphy T.V. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr. 121:1992;187-194.
34. Seppala I., Makela O. Antigenicity of dextran-protein conjugates in mice. Effects of molecular weight of the carbohydrate and comparison of two modes of coupling. J Immunol. 143:1989;1259-1264.
35. Anderson P.W., Pichichero M.E., Stein E.C., Porcelli S., Betts R.F., Connuck D.M., Korones D., Insel R.A., Zahradnik J.M., Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM 197. J Immunol. 142:1989;2464-2468.
36. Peeters C.M.A.M., Evenberg D., Hoogerhout P., Kayhty H., Saarinen L., van Boeckel C.A.A., vanderMarel G.A., vanboom J.H., Poolman J.T. Synthetic trimer and tetramer of 3-β-D-ribose-1-1)-D-ribitol-5-phosphate conjugated to protein induce antibody responses to Haemophilus influenzae type b capsular polysaccharide in mice and monkeys. Infect Immun. 60:1992;1826-1833.
37. Pillai S., Ciciriello S., Koster M., Eby R. Distinct pattern of antibody reactivity with oligomeric or polymeric forms of the capsular polysaccharide of Haemophilus influenzae type b. Infect Immun. 59:1991;4371-4376.
38. Chong P., Chan N., Kandil A., Tripet B., James O., Yang Y., Shi S., Klein M. A strategy for rationale design of fully synthetic glycopeptide conjugate vaccines. Infect Immun. 65:1997;4918-4925.